In Vivo: strategic insights for life sciences decision-maker...
By Lucie Ellis 30 Sep 2020
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices.”
In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging.
There is a need for the development of more mHealth apps in oncology settings, considering the increasing disease burden and potential clinical benefit. According to Cancer Research UK, there were 17 million cases of cancer and 9.6 million deaths globally in 2018. This is estimated to increase substantially to 27.5 million incident cases by 2040.
How Are Apps Helping Researchers?
In recent years health care delivery has moved back to the community and away from traditional care organizations such as hospitals. There are now several prevention initiatives, including mHealth, that are working with the community (users) to increase health care access, inform behavioral change and facilitate data collection. MHealth apps from pharmaceutical companies are providing personalized health care by giving patients the ability to track and monitor their disease. MHealth initiatives along with app-accompanied randomized controlled trials (RCTs), called smart RCTs, and app-based studies are expected to drive future medical research.
Conducting traditional research has always been challenging for numerous reasons, including biased samples not representative of the population as a whole, skewed responses/self-reported data and a lack of standardization of methods. MHealth apps can counter these design flaws by tracking activity and other health-related data more accurately and efficiently. They also have the flexibility to experiment and determine how to effectively engage with users to help them achieve their goals. With the use of apps, users can quickly opt-in to research studies relating to their health conditions, saving time and money for researchers. There are also no geographical limitations, and apps can capture significantly more data to help understand a disease better. This also means patient data can be sent directly to researchers more easily and frequently than if patients were required to travel to give samples or perform tests.
How Are Apps Helping Cancer Patients?
Cancer patients often experience a long, and frequently stressful, personal care journey. Cancer mHealth apps can help promote better patient-doctor communication and encourage shared decision-making during treatment. After treatment, apps can ease follow-up care and help patients deal with side effects or make behavioral changes to improve their quality of life.
There are several apps on the market and in development aimed at providing cancer patients with more personalized care by tracking symptoms, patient journeys, treatment side effects and successes. Select examples include:
> Share the Journey. This is an interactive research study that aims to understand why some breast cancer survivors recover more quickly than others, and why their symptoms vary. The app tracks five common consequences of breast cancer treatment: fatigue, cognitive function, sleep disturbances, mood changes and exercise performance. The plan is to use the resulting data for further research that may lead to interventions and facilitate more personalized treatments.
> TapCloud. This product aims to simplify complex care plans of cancer patients into daily steps, customize care plans for any disease condition, track patient health and compliance in real time, and identify which patients need help and patient management. For instance, after surgery, the TapCloud platform adjusts to include advice for how best to recover. In the app, patients see a word cloud filled with phrases like “OK”, “stuffy”, “bloated”, and “good.” They are then invited to tap on the words that apply to them, with personalized treatment follow-up.
> My Cancer Circle. An online tool created by Boehringer Ingelheim in collaboration with CancerCare, the app is designed help caregivers build their own community of support. It allows caregivers to coordinate activities such as bringing meals or transporting patients to their appointments. My Cancer Circle also provides a private space where users can offer words of support and encouragement.
Research On User Behavior And Usefulness Of Apps
A US-based consumer survey, conducted by Deloitte and published in 2018, reported findings on attitudes and behaviors across a patient journey; that is, searching for health care, accessing new care, and sharing personal health information. The report observed that about one-third of users were interested in using apps for identifying symptoms, advice on nutrition, exercise, sleep, and stress management, as well as directing them to a physician or nurse. It was interesting to note that users who considered themselves to be in excellent or very good health and those in poor health were more likely to use these apps when compared with those in moderate health. In all, 60% of surveyed users said that they were willing to share personal health data with their doctor to improve their health, with chronically ill users more likely to share tracked information. Overall, the use of tools for measuring fitness and other health improvement goals increased from 17% in 2013 to 42% in 2018.
A patient survey from JMIR mHealth and uHealth analyzed cancer patients’ acceptance regarding app use and investigated the functions of cancer care health apps that are most required, and the main reasons to refuse app-assisted cancer care. Of all patients, almost half (48.5%) were willing to send data to their treating clinic from their app, and among them about two-thirds believed that additional and regularly sent data are helpful.
Moreover, the vast majority (86.8%) wanted to be contacted when user-entered data showed irregularities. The main reasons for those who indicated they would refuse app use (43%) were: lack of skills, concerns about the use of data, lack of capable devices, and personal contact with the treating physician. The survey also reported that there was a significant relationship between patient demographic and app use, favoring males and patients aged 18-39 years. Also, it was interesting to note that those using cancer health apps were also using other mHealth apps such as running apps or tracking apps for blood sugar, heart rate or weight reduction.
In terms of the usefulness of mHealth in cancer prevention and care, apps have provided effective methods to conduct clinical trials by improving recruitment of patients, in addition to examples demonstrating improved quality of life and even better survival rates. The Metastatic Breast Cancer Project, for example, was able to recruit more than 2,000 patients in every US state in a span of seven months by using social media and a website, which otherwise would not have been possible. The project was aimed at examining factors that trigger breast cancer metastasis at a genomic level using patient tissue.
Another example is the Moovcare app that is used to detect cancer relapse or complications in Stage III/IV lung cancer patients during follow-up assigned through a web or app interface. A research study presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting reported that Moovcare improved patients’ quality of life considerably. One of the most important findings of this report was that after one year of follow-up, 75% of app users were still alive, compared to 49% of non-users.
A review in 2019 by JMIR mHealth and uHealth that analyzed mHealth apps specific to breast cancer also revealed broad positive benefits. It was shown that breast cancer patients who participated in mHealth-based interventions had greater effects of weight loss, improved quality of life and less stress. However, the study noted that there is a need for stricter regulation, and apps need to be extensively research-tested for their utility, effectiveness and safety before making them available to the public. A separate study that assessed the quality of mHealth apps observed huge heterogeneity in assessment criteria for the apps in different studies, either due to the various assessment approaches used by researchers or different definitions for each criterion. Therefore, it seems necessary to reach a consensus among experts on definitions and assessment criteria. Addressing these points will lead to the improvement of existing mHealth tools and the development of more comprehensive apps.
The future Of MHealth Apps
There is a need for app developers and organizations working with health data to build trust to encourage users to share their personal information. The 2019 JMIR mHealth and uHealth report pointed out that one way to do this is to let users own their health records. Data often reside in multiple places across different providers, which makes valuable pieces of information and a complete picture of one’s health unavailable to doctors, researchers and the users themselves. This makes it difficult for health care systems to target care when most needed. Organizations are working towards this goal, including Apple, which released the Health feature on its smartphones that collates and centralizes the medical history and data of its users.
On similar lines, the mHealth start-up Ciitizen is providing cancer patients access to their own records, such as lab results, images and genetic information, that can be shared digitally. Such efforts to improve the accessibility of health data will be essential for the clinical potential of mHealth to be realized, both in the treatment of cancer and general health care.
In Vivo: strategic insights for life sciences decision-maker...
30 Sep 2020
COVID-19 has created an “always accessible” online work environment conducive to executive recruiting, although some candidates are hesitant to change...
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: